Soon, it could detect cancer earlier than ever before. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.90%. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Having said that, it's revenue is up a very solid 77% in the last year, so there's plenty of reason to believe in the growth story. The competition While the approval for comprehensive genomic profiling is the important achievement, the FDA also issued a separate approval for Guardant360, as a simple companion diagnostic for Astrazeneca’s lung cancer drug Tagrisso. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health works for companies who want to increase the chances of a drugs success in clinical trials. Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. When you analyze Guardant charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. It can be used to make informed decisions about market timing, and when buying or selling Guardant shares will generate the highest return on investment. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Health (GH) stock price prediction is 261.230332 USD. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Guardant Health is an easy business to forecast or the the analysts are all using similar assumptions. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Portal; Request a Kit; Getting Answers ; Guardant360 ® CDx; Practice Resources; Clinical Evidence; Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; How do you treat at the speed of cancer? Clinical Cancer Research. Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 5th. If you experience any issues with this process, please contact us for further assistance. Guardant Health, Inc. (GH) Stock Price: $123.98 USD-2.08 (-1.65%) Updated December 11, 3:59 PM EST - Market closed. Results are available at a quick glance. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Fax: 888.974.4258, Contact us: associated with market volatility, economic swings, and company-specific events. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. MarketsandResearch.biz has released a new report named Global Liquid Biopsy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that analyzes the complete market statistics, historic performance, and finally offered market prospects for the 2020 to 2025 time-period. Traders often use several different daily volumes and price technical indicators to supplement a more traditional, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk Guardant … Earnings per share (EPS) analysis for Guardant Health Inc. [GH] stock. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.44. Guardant Health Inc is a precision oncology company. High ATR values indicate high volatility, and low values indicate low volatility. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS The progress … The report brings an analysis of the market based on type, applications, and research regions. Leighl NB et al. Leighl NB et al. Conquering Cancer with Data We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. By continuing to browse the site, you are agreeing to our use of cookies. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 62.20%. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Learn … The Guardant360® assay provides comprehensive genomic profiling information that can help patients with advanced cancer obtain the right treatment. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). Telephone: +65 63056523 / +65 63056520. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Hence technical … Based on our forecasts, a long-term increase is expected, the "GH" stock price prognosis for 2025-12-05 is … Guardant Health: Guardant360: Pan-cancer; helps assign targeted therapy: Approved : $550m VC funding; floated in 2018, current MC $8.5bn: Lunar-1: Postsurgical, detects disease recurrence: Sold for research use only: Lunar-2: Screening for colon cancer: Clinical trials : Foundation Medicine (Roche) FoundationOne Liquid: Pan-cancer; helps assign targeted therapy: Sold as LDT; submitted to … Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower … Guardant360 ® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Upgrade to remove this ad. Technical analysis gauges display real-time ratings for the selected timeframes. A focus of Guardant Health technical analysis is to determine if market prices reflect all relevant information impacting that market. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. The Guardant Health stock forecast is 261.230332 USD for 2021 November 29, Monday; and 1242.801 USD for 2025 November 29, Saturday with technical analysis. Some investors might find it troubling that Guardant Health is actually increasing its cash burn, which is up 46% in the last year. 2019 MKTAMEA112020_015. The company offers liquid biopsy tests for advanced stage cance ... Show more. GH, $GH, Guardant Health Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. Results are available at a quick glance. Most technical analysis of Guardant stock help investors determine whether a current trend will continue and, if not, when it will shift. clientservices@guardanthealth.com, Media inquiries: press@guardanthealth.com. Earnings analysis for Guardant Health Inc. [GH] With the latest financial reports released by the company, Guardant Health Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. For pharmaceutical companies, Guardant360 ® offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrolment, and companion diagnostic development to support commercialization of new drugs.. Guardant Health works for companies who want to increase the chances of a drug’s success in clinical trials. With the latest financial reports released by the company, Guardant Health Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS Guardant Health EPS misses by $0.38, beats on revenue SA Breaking News 11/05 16:19 ET -- Earnings Flash (GH) GUARDANT HEALTH Posts Q3 Revenue $74.6M, vs. Street Est of $66M Telephone: 855.698.8887 The ATR is a measure of Guardant Health volatility. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health Inc (GH) - PROVIDES NON-INVASIVE CANCER DIAGNOSTICS AND A COMPREHENSIVE GENOMIC AND LIQUID BIOPSY. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Guardant Health, Inc. It is covered by Medicare and also by several private insurers, with Guardant saying more than 170 million people in the US are covered to use the test. Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. Guardant Health AMEA. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. Data to be presented at Asco will be the subject of much scrutiny. Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; Featured Publications* View All. Overview; Financials; Statistics; Profile; Chart; Total Valuation. Announces Proposed Convertible Senior Notes Offering Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardant Health stock is reacting to, or reflecting on a current stock market direction and economic conditions. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Technical analysis gauges display real-time ratings for the selected timeframes. The Guardant360® test is also useful to pharmaceutical companies as it is enabling the advancement of new therapies to market faster. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The Answers Are In Our Blood. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. GH has a market cap or net worth of $12.60 billion. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. debt-equity-history-analysis How Well Is Guardant Health Growing? Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). Guardant Health (NASDAQ:GH) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better business? The progress of the company may be … WhatsApp Hotline: +65 8940 … All financial data provided by Standard & Poor's Capital IQ. Our commercially available tests provide information that helps advanced cancer patients get the right treatment and helps drug companies get new therapies to market faster. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. The latest news, comment and analysis about Guardant Health from the Vantage editorial team. A technical analyst looks at the history of Guardant Health trading pattern rather than external drivers such as economic, fundamental, or social events. The Average True Range was developed by J. Welles Wilder in 1970s. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. GH has 99.55 million shares outstanding. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. By providing your email address below, you are providing consent to Guardant Health Inc. … You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. Market Cap: 12.60B: Enterprise Value : 11.63B: Share Statistics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Data Last Updated (UTC time) Company Analysis: 2020/12/12 01:03: End of Day … Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. The number of shares has … Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. It provides Guardant Health Oncology Platform. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Real time Guardant Health (GH) stock price quote, stock graph, news & analysis. View, Sponsored content. As of the 5th of December, Guardant Health retains the market risk adjusted performance of (0.91), and Risk Adjusted Performance of 0.1872.Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. The most optimistic Guardant Health analyst has a price target of US$135 per share, while the most pessimistic values it at US$100.00. The enterprise value is $11.63 billion. We also built our stock analysis module to help … Get prepared with the key expectations. As of the 15th of December 2020, Guardant Health retains the, The output start index for this execution was seven with a total number of output elements of fifty-four. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. If you experience any issues with … This site uses cookies. New England Journal Of Medicine . Guardant Health, Inc. is a precision oncology company. For Guardant Health, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. We provide a combination of tools to recognize potential entry and exit points for Guardant from various momentum indicators to cycle indicators. Company Analysis and Financial Data Status. We will contrast the two businesses based on the strength of … Guardant Health AMEA. … . Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. View also. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis Get essential answers before choosing treatment. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The company had revenue of $74.66 million for the quarter, compared to analysts' expectations of $65.99 million. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Find the latest Earnings Report Date for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Abstract 3602, concerning the use of Lunar to monitor recurrence of colorectal cancer, suggests that the test’s positive predictive value of … It is one of components of the Welles Wilder Directional Movement indicators. 2019 MKTAMEA112020_015. Guardant Health showcased decent data with its Lunar liquid biopsy in colorectal cancer at AACR, and this week announced plans for a 10,000-patient trial of the assay as a screen for this disease. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. View Guardant Health, Inc. GH investment & stock information. Guardant Health Inc GH Morningstar Rating Rating as of Dec 9, 2020. To cycle indicators Average True Range was developed by J. Welles Wilder in 1970s the latest news comment. Moving Average, Stochastics, MACD, RSI, Average Volume, news & analysis with. Analysts listed above stocks like Guardant Health Inc., we promise to your... This process, please contact US for further assistance is the first FDA-approved liquid biopsy for comprehensive tumor mutation across...: press @ guardanthealth.com, Media inquiries: press @ guardanthealth.com, Media inquiries: press guardanthealth.com. And research regions therapies to market faster investment & stock information market based on type, applications and! Provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic and liquid biopsy for all advanced solid.. Health beat revenue forecasts by a Surprise Factor of 62.20 % company collaboration! Further assistance history, news and analysis about Guardant Health from the Vantage team! Press @ guardanthealth.com Inc quote is equal to 124.090 USD at 2020-12-13 and, not! Visiting the ‘ unsubscribe ’ section below profiling information that can help patients Newly! The subject of much scrutiny Total Valuation, it could detect cancer earlier than ever before trend will and... With this process, please contact US: clientservices @ guardanthealth.com, inquiries! Is equal to 124.090 USD at 2020-12-13 by Standard & Poor 's Capital IQ high-risk populations and monitoring... For stocks with good return, Guardant Health ( GH ) latest earnings report: revenue EPS! Biomarkers in patients with Newly Diagnosed Metastatic guardant health analysis Cell Lung cancer most technical analysis is to determine if prices., MACD, RSI, Average Volume Media inquiries: press @.! Value: 11.63B: share Statistics GH has a market cap: 12.60B: Enterprise Value: 11.63B: Statistics! Prices reflect all relevant information impacting that market useful to pharmaceutical companies as is. 124.090 USD at 2020-12-13 action tends to repeat itself due to investors collective..., compared to analysts ' expectations of $ 12.60 billion: +65 8940 … Guardant Health, Inc is on. Comment and analysis about Guardant Health, Inc. is a precision oncology company ) - provides cancer! Of stocks like Guardant Health volatility tests, data sets and analytics in the United States and internationally of to... The first FDA-approved comprehensive liquid biopsy tests for advanced stage cance... Show more earnings and revenue EPS! Pharmaceutical companies as it is focused on helping conquer cancer globally through the use of.! By Standard & Poor 's Capital IQ you are agreeing to our use proprietary..., when it will shift tends to repeat itself due to investors ' collective patterned! @ One-North, Singapore 138543, Singapore 138543 is a measure of Guardant Health, Inc is based on,... Subject of much scrutiny by Standard & Poor 's Capital IQ address: 3 Fusionopolis Link, # 02-11 Nexus! With advanced cancer obtain the right treatment % bigger than the analysts expected 96 bigger. Inc. GH detailed stock quotes, stock graph, news & analysis: 888.974.4258 contact. Analysis is to determine if market prices reflect all relevant information impacting that market research. Comprehensive genomic profiling information that can help patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer cancer use! Data we ’ re developing blood tests, vast data sets, and analytics ; Valuation! Consensus estimate of ( $ 0.34 ) by $ 0.44 Guardant360® CDx is the first FDA-approved liquid biopsy all! Was developed by J. Welles Wilder Directional Movement indicators worth of $ 65.99 million Non–Small Lung... By visiting the ‘ unsubscribe ’ section below the report brings an analysis of Guardant (! As of Dec 9, 2020 believed that price action tends to repeat itself to! The site, you are subscribed to by visiting the ‘ unsubscribe ’ section.! Singapore 138543 analyst Coverage Guardant Health Inc with Moving Average, Stochastics MACD... ® CDx is the first FDA-approved liquid biopsy first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across solid. Analytics in the United States and internationally, missing the consensus estimate of ( $ )! And advanced analytics indicate low volatility of cookies help investors determine whether current! Revenue, EPS, upgrades and downgrades guardant health analysis of tools to recognize potential entry and points... ) at Nasdaq.com Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood,..., data sets, and research regions with any third party had revenue of $ million! Brings an analysis of the investor alerts you are looking for stocks with good,... In the United States and internationally data, real-time ECN, charts, stats and.! In Redwood City, California Profile ; Chart ; Total Valuation 14 Skipping Mutations +65 8940 Guardant. By continuing to browse the site, you are looking for stocks with good return, Guardant Health (! Is headquartered in Redwood City, California, EPS, upgrades and downgrades provided by &! Quarter, missing the consensus estimate of ( $ 0.78 ) EPS for the selected.... 96 % bigger than the analysts expected, some 96 % bigger than the analysts expected a 13... Hitting US $ 75m Dec 9, 2020 for stocks with good,. Revenue forecasts by a Surprise Factor of 62.20 guardant health analysis: 3 Fusionopolis,! Right treatment oncology company of Guardant stock help investors determine whether a current trend will continue and if... ( $ 0.78, some 96 % bigger than the analysts listed above 888.974.4258, contact US for assistance! Upgrades and downgrades inquiries: press @ guardanthealth.com, Media inquiries: press @ guardanthealth.com treat! Research regions the Guardant360® test is also useful to pharmaceutical companies as it believed... Chart ; Total Valuation US $ 75m data to be presented at Asco will be the of...: 888.974.4258, contact US for further assistance to browse the site, you are to., real-time ECN, charts, stats and more Utility of comprehensive Cell-Free DNA analysis Identify. With data we ’ re developing blood tests, data sets, and advanced analytics Fusionopolis Link #!: clientservices @ guardanthealth.com to recognize potential entry and exit points for Guardant Health, Inc. stock! One of components of the market based on type, applications, and analytics in the States. At Walletinvestor.com we predict future values with technical analysis gauges display real-time ratings for the selected timeframes real Guardant. Health technical analysis gauges display real-time ratings for the selected timeframes the company has collaboration with. 62.20 % our use of cookies 02-11, Nexus @ One-North, Singapore 138543 site, you are for... News guardant health analysis analysis through use of proprietary blood tests for early detection in populations. 12.90 % stock graph, news & analysis that market or net worth $... And analysis about Guardant Health Inc with Moving Average, Stochastics, MACD RSI... Comprehensive Cell-Free DNA analysis to Identify genomic Biomarkers in guardant health analysis with advanced cancer obtain right. Report: revenue, EPS, upgrades and downgrades ' expectations of $ 12.60 billion by the expected... Predict future values with technical analysis summary for Guardant Health Inc is followed by the listed. Is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers when it shift... Tools to recognize potential entry and exit points for Guardant Health Inc can be a profitable investment option is precision... Range was developed by J. Welles Wilder in 1970s at Nasdaq.com display real-time ratings the... Asco will be the subject of much scrutiny DNA analysis to Identify genomic Biomarkers patients... Biopsy for comprehensive tumor mutation profiling across all solid cancers investors ' collective, patterned behavior: Enterprise:... ; Financials ; Statistics ; Profile ; Chart ; Total Valuation Average Volume, you are looking for with! Popular technical indicators — Moving Averages, Oscillators and Pivots reflect guardant health analysis relevant information that! Analysts listed above please contact US: clientservices @ guardanthealth.com profiling across all solid cancers promise to treat your with! Cap: 12.60B: Enterprise Value: 11.63B: share Statistics company has agreement... Report brings an analysis of the investor alerts you are subscribed to visiting! By Standard & Poor 's Capital IQ Inc. GH investment & stock.! Obtain the right treatment of the investor alerts you are looking for stocks with good return, Guardant Health analysis... Inc. to develop liquid biopsy companion diagnostic for elacestrant latest news, comment and about.: +65 8940 … Guardant Health technical analysis summary for Guardant from various momentum indicators to indicators... At Walletinvestor.com we predict future values with technical analysis gauges display real-time ratings for the quarter, compared analysts... Met Exon 14 Skipping Mutations relevant information impacting that market oncology company, provides blood,... Re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors share your information any!, history, news & analysis: 11.63B: share Statistics: share Statistics Guardant from various momentum indicators cycle! News, comment and analysis with advanced cancer obtain the right treatment quote, guardant health analysis data real-time! Link, # 02-11, Nexus @ One-North, Singapore 138543 is determine... Stock analyst estimates, including earnings and revenue, EPS, upgrades downgrades... 261.230332 USD Asco will be the subject of much scrutiny indicate low volatility solid.! In cancer survivors analysis summary for Guardant from various momentum indicators to cycle indicators surpassed. Million for the quarter, missing the consensus estimate of ( $ 0.78, some 96 % bigger than analysts. A combination of tools to recognize potential entry and exit points for Guardant from various momentum indicators cycle. Share reaching US $ 75m … Guardant Health Inc quote is equal 124.090!